Suppr超能文献

大鼠脑中多巴胺受体对芳香族L-氨基酸脱羧酶的调节作用。

Regulation of aromatic L-amino acid decarboxylase by dopamine receptors in the rat brain.

作者信息

Zhu M Y, Juorio A V, Paterson I A, Boulton A A

机构信息

Neuropsychiatric Research Unit, University of Saskatchewan, Saskatoon, Canada.

出版信息

J Neurochem. 1992 Feb;58(2):636-41. doi: 10.1111/j.1471-4159.1992.tb09765.x.

Abstract

Decarboxylation of phenylalanine by aromatic L-amino acid decarboxylase (AADC) is the rate-limiting step in the synthesis of 2-phenylethylamine (PE), a putative modulator of dopamine transmission. Because neuroleptics increase the rate of accumulation of striatal PE, these studies were performed to determine whether this effect may be mediated by a change in AADC activity. Administration of the D1 antagonist SCH 23390 at doses of 0.01-1 mg/kg significantly increased rat striatal AADC activity in an in vitro assay (by 16-33%). Pimozide, a D2-receptor antagonist, when given at doses of 0.01-3 mg/kg, also increased AADC activity in the rat striatum (by 25-41%). In addition, pimozide at doses of 0.3 and 1 mg/kg increased AADC activity in the nucleus accumbens (by 33% and 45%) and at doses of 0.1, 0.3, and 1 mg/kg increased AADC activity in the olfactory tubercles (by 23%, 30%, and 28%, respectively). Analysis of the enzyme kinetics indicated that the Vmax increased with little change in the Km with L-3,4-dihydroxyphenylalanine as substrate. The AADC activity in the striatum showed a time-dependent response after the administration of SCH 23390 and pimozide: the activity was increased within 30 min and the increases lasted 2-4 h. Inhibition of protein synthesis by cycloheximide (10 mg/kg, 0.5 h) had no effect on the striatal AADC activity or on the increases in striatal AADC activity produced by pimozide or SCH 23390. The results indicate that the increases in AADC activity induced by dopamine-receptor blockers are not due to de novo synthesis of the enzyme.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

芳香族L-氨基酸脱羧酶(AADC)催化苯丙氨酸脱羧是2-苯乙胺(PE)合成中的限速步骤,PE被认为是多巴胺传递的调节剂。由于抗精神病药物会增加纹状体PE的积累速率,因此进行了这些研究以确定这种效应是否可能由AADC活性的变化介导。在体外实验中,以0.01-1mg/kg的剂量给予D1拮抗剂SCH 23390可显著提高大鼠纹状体AADC活性(提高16%-33%)。以0.01-3mg/kg的剂量给予D2受体拮抗剂匹莫齐特,也可提高大鼠纹状体中的AADC活性(提高25%-41%)。此外,0.3和1mg/kg剂量的匹莫齐特可提高伏隔核中的AADC活性(分别提高33%和45%),0.1、0.3和1mg/kg剂量的匹莫齐特可提高嗅结节中的AADC活性(分别提高23%、30%和28%)。酶动力学分析表明,以L-3,4-二羟基苯丙氨酸为底物时,Vmax增加而Km变化不大。给予SCH 23390和匹莫齐特后,纹状体中的AADC活性呈现时间依赖性反应:活性在30分钟内增加,且增加持续2-4小时。用环己酰亚胺(10mg/kg,0.5小时)抑制蛋白质合成对纹状体AADC活性或匹莫齐特或SCH 23390引起的纹状体AADC活性增加没有影响。结果表明,多巴胺受体阻滞剂诱导的AADC活性增加并非由于酶的从头合成。(摘要截短至250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验